NASDAQ · ESTA

Establishment Labs Holdings Inc.

$92.10 -$0.22 (-0.24%) 1D After hours

Key Metrics

$2.72B
Market cap
P/E · TTM
$229.58M
Revenue · TTM
−$43.74M
Net income
EPS · TTM $-1.48
Dividend yield
Free cash flow −$41.62M
Beta · 1Y 1.40
EBITDA · TTM −$45.12M
Gross margin 70.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 30
    The stock moved +9.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 30
  • Mar 30
    From its Feb 24 high, the share price fell 31%.

    Peak close $79.67 on Feb 24; trough close $54.69 on Mar 30. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -31%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.72B
Enterprise value$2.90B
Shares outstanding29.4M
52-wk range$33.35 – $96.99
Avg volume · 20D302.7K
Net cash −$180.49M
Book value / share$0.50
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
ExchangeNASDAQ
About Establishment Labs Holdings Inc.
IPO dateJul 19, 2018
Employees1004

Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S11.83
P/FCF
EV/EBITDA
EV/Sales12.62
Graham №

Profitability

Gross 70.1%
Operating -22.4%
Net -19.1%
FCF -18.1%
ROE / ROIC -128.9% · -22.4%

Financial Health

Current ratio2.96
Quick ratio1.91
Debt / equity16.82
Debt / EBITDA -5.51
Net cash −$180.49M
Working capital$162.67M

Cash Flow · TTM

Operating CF −$34.48M
Capex −$7.15M
Free cash flow −$41.62M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

3.5
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings